Association of adiponectin, interleukin (IL)-1ra, inducible protein 10, IL-6 and number of islet autoantibodies with progression patterns of type 1 diabetes the first year after diagnosis

Clinical and Experimental Immunology

Volumn 161, Issue 3, 2010, Pages 444-452

  Kaas, A ^a   Pfleger, C ^c   Hansen, L ^a   Buschard, K ^b   Schloot, N C ^a,d   Roep, B O ^e   Mortensen, H B ^a  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adiponectin; C peptide; Paediatric; Residual beta cell function; Type 1 diabetes

Indexed keywords

ADIPONECTIN; C PEPTIDE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUTAMATE DECARBOXYLASE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; LEUKOCYTE ANTIGEN; PANCREAS ISLET CELL ANTIBODY;

ADOLESCENT; ARTICLE; CELL FUNCTION; CHILD; DISEASE COURSE; FEMALE; HUMAN; INFANT; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET BETA CELL; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADIPONECTIN; ADOLESCENT; AUTOANTIBODIES; C-PEPTIDE; CHEMOKINE CXCL10; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; FEMALE; HUMANS; INFANT; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-6; MALE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 77955738951     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04193.x     Document Type: Article

References (33)

1. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001 358 : 221 229.
2. The Diabetes Control and Complications Trial (DCCT) Research Group. Effects of age, duration and treatmentof insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987 65 : 30 6.
3. Schloot NC, Hanifi-Moghaddam P, Abenhus-Andersen N et al. Association of immune mediators at diagnosis of Type 1 diabetes with later clinical remission. Diabet Med 2007 24 : 512 520.
4. Spranger J, Kroke A, Mohlig M et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003 361 : 226 228.
5. Kubota N, Terauchi Y, Yamauchi T et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002 277 : 25863 25866.
6. Huerta MG. Adiponectin and leptin: potential tools in the differential diagnosis of pediatric diabetes? Rev Endocr Metab Disord 2006 7 : 187 196.
7. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001 7 : 947 953.
8. Imagawa A, Funahashi T, Nakamura T et al. Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care 2002 25 : 1665 1666.
9. Frystyk J, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 2005 48 : 1911 1918.
10. Celi F, Bini V, Papi F et al. Circulating adipocytokines in non-diabetic and Type 1 diabetic children: relationship to insulin therapy, glycaemic control and pubertal development. Diabet Med 2006 23 : 660 665.
11. Rotondi M, Chiovato L, Romagnani S, Serio M, Romagnani P. Role of chemokines in endocrine autoimmune diseases. Endocr Rev 2007 28 : 492 520. (Pubitemid 41317848)
12. Nicoletti F, Conget I, Di MM et al. Serum concentrations of the interferon-gamma-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 2002 45 : 1107 1110.
13. Shimada A, Morimoto J, Kodama K et al. Elevated serum IP-10 levels observed in type 1 diabetes. Diabetes Care 2001 24 : 510 515.
14. Rotondi M, Romagnani P, Brozzetti A et al. Serum concentrations of the interferon-alpha-inducible chemokine IP-10/CXCL10 are augmented in both newly-diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 45 : 1107 1110. Diabetologia 2003 46 : 1020 1021.
15. Rotondi M, Lazzeri E, Romagnani P, Serio M. Role for interferon-gamma inducible chemokines in endocrine autoimmunity: an expanding field. J Endocrinol Invest 2003 26 : 177 180.
16. Carey AL, Steinberg GR, Macaulay SL et al. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 2006 55 : 2688 2697.
17. Pfleger C, Mortensen HB, Hansen L et al. Association of IL-1ra and adiponectin with C-peptide and remission in patients with type 1 diabetes. Diabetes 2008 57 : 929 937.
18. Mortensen HB, Hougaard P, Swift P et al. New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care 2009 32 : 1384 1390.
19. Mortensen HB, Swift PG, Holl RW et al. Multinational study in children and adolescents with newly diagnosed type 1 diabetes: association of age, ketoacidosis, HLA status, and autoantibodies on residual beta-cell function and glycemic control 12 months after diagnosis. Pediatr Diabetes 2008.
20. Marcel GJ. Genomic analysis of the human MHC. DNA based typing for HLA alleles and linked polymorphisms. Tilanus IHWG technical manual. Distributed by the International Histocompatibility Working Group, IHWG Press c/o Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA. 2001: ISBN number: 0-945278-02-02-0.
21. Muller S, Martin S, Koenig W et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 2002 45 : 805 812.
22. Hanifi-Moghaddam P, Schloot NC, Kappler S, Seissler J, Kolb H. An association of autoantibody status and serum cytokine levels in type 1 diabetes. Diabetes 2003 52 : 1137 1142.
23. Martin S, Pawlowski B, Greulich B, Ziegler AG, Mandrup-Poulsen T, Mahon J. Natural course of remission in IDDM during 1st yr after diagnosis. Diabetes Care 1992 15 : 66 74.
24. Bonfanti R, Bognetti E, Meschi F et al. Residual beta-cell function and spontaneous clinical remission in type 1 diabetes mellitus: the role of puberty. Acta Diabetol 1998 35 : 91 5.
25. Wallensteen M, Dahlquist G, Persson B et al. Factors influencing the magnitude, duration, and rate of fall of B-cell function in type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosis. Diabetologia 1988 31 : 664 669.
26. Greenbaum CJ, Mandrup-Poulsen T, McGee PF et al. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008 31 : 1966 1971.
27. Muhammad BJ, Swift PG, Raymond NT, Botha JL. Partial remission phase of diabetes in children younger than age 10 years. Arch Dis Child 1999 80 : 367 369.
28. Couper J, Donaghue K. Phases of diabetes. Pediatr Diabetes 2007 8 : 44 7.
29. Sochett EB, Daneman D, Clarson C, Ehrlich RM. Factors affecting and patterns of residual insulin secretion during the first year of type 1 (insulin-dependent) diabetes mellitus in children. Diabetologia 1987 30 : 453 459.
30. Schiffrin A, Suissa S, Poussier P, Guttmann R, Weitzner G. Prospective study of predictors of beta-cell survival in type I diabetes. Diabetes 1988 37 : 920 925.
31. von HM, Sanda S, Herold K. Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol 2007 7 : 988 994.
32. Yamauchi T, Kamon J, Minokoshi Y et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002 8 : 1288 1295.
33. Christen U, McGavern DB, Luster AD, von Herrath MG, Oldstone MB. Among CXCR3 chemokines, IFN-gamma-inducible protein of 10 kDa (CXC chemokine ligand (CXCL) 10) but not monokine induced by IFN-gamma (CXCL9) imprints a pattern for the subsequent development of autoimmune disease. J Immunol 2003 171 : 6838 6845.